Corvus Pharmaceuticals, Inc. (CRVS)
$0.7216
Rating:
Recommendation:
Neutral
| Symbol | CRVS |
|---|---|
| Price | $0.7216 |
| Beta | 1.036 |
| Volume Avg. | 0.10M |
| Market Cap | 33.593M |
| Shares () | - |
| 52 Week Range | 0.607-2.11 |
| 1y Target Est | - |
| DCF Unlevered | CRVS DCF -> | |
|---|---|---|
| DCF Levered | CRVS LDCF -> | |
| ROE | -79.71% | Strong Sell |
| ROA | -84.95% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 21.61% | Neutral |
| P/E | -0.90 | |
| P/B | 0.60 | Buy |
Latest CRVS news
About
Download (Excel)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.